About Us

Overview

Syntimmune approaches areas of high unmet medical need in a unique way.

Instead of searching for novel, unproven disease biology, Syntimmune focuses on areas of science that are well understood and extensively researched. We seek new treatments that build on these areas of scientific consensus and broad applicability.

In the case of our lead drug candidate, SYNT001, both the cellular pathway and the specific molecular target have been studied extensively for more than 25 years, spearheaded by the groundbreaking research of the scientific team behind Syntimmune. Building on proven areas of science enables Syntimmune to advance its drug candidates swiftly and predictably.

The result is a significantly derisked approach to new drug development. More importantly, we believe our approach speeds approval of medicines for patients in areas where existing treatments involve inconvenience, dangerous side effects, or poor efficacy. In an industry that often places a premium on novelty, Syntimmune understands that creating real value comes from helping patients who are suffering with diseases for which current treatments are inadequate or nonexistent.

Background

Founders

Richard Blumberg, M.D.

Scientific Founder, Director and Chairman of the Scientific Advisory Board

Laurence Blumberg, M.D.

Business Founder, Director, President and Chief Operating Officer

Management

David De Graaf, Ph.D.

Chief Executive Officer

Laurence Blumberg, M.D.

President and Chief Operating Officer

Susan D. Jones, Ph.D.

Senior Vice President, CMC

Ryan Iarrobino

Senior Vice President, Clinical Operations and Data Management

Leslie Stolz, Ph.D.

Vice President, Regulatory Strategy

Board of Directors

Burt Adelman, M.D.

Senior advisor, Syntimmune

Seth Harrison, M.D.

Apple Tree Partners

Sam Hall, Ph.D.

Apple Tree Partners

Aaron Kantoff

Apple Tree Partners

Scientific Advisory Board

Richard Blumberg, M.D.

Chairman, Scientific Advisory Board
Harvard Medical School

Wayne Lencer, M.D.

Harvard Medical School

Inger Sandlie, Ph.D.

University of Oslo

Derry Roopenian, Ph.D.

The Jackson Laboratory

Alan Bitonti, Ph.D.

Senior Advisor

Investors

apple-tree-partners-logo2
partners-innovation
fmb
afb_fund-90